Close Menu
Chicago News Journal
    Facebook X (Twitter) Instagram
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Facebook X (Twitter) Instagram YouTube TikTok
    Chicago News JournalChicago News Journal
    • Home
    • US News
    • Politics
    • Business
    • Science
    • Technology
    • LifeStyle
    • Music
    • Television
    • Film
    • Books
    • Contact
      • About us
      • Amazon Disclaimer
      • DMCA / Copyrights Disclaimer
      • Privacy Policy
      • Terms and Conditions
    Chicago News Journal
    Home»Business

    Novo Nordisk shares rise after Wegovy obesity pill launch

    AdminBy AdminJanuary 17, 2026 Business
    Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram
    Novo Nordisk shares rise after Wegovy obesity pill launch

    A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026.

    George Frey | Bloomberg | Getty Images

    Shares of Novo Nordisk rose more than 8% on Friday after early prescription data showed an encouraging start to the U.S. launch of the company’s new GLP-1 pill for obesity.

    In a Friday note, TD Cowen analysts called it a “solid start” for the first-ever weight loss pill, but said “one data point does not make a trend.” They cautioned that they need to see more data to fully assess early demand for the Wegovy pill, which officially launched Jan. 5 after winning approval in late December. 

    Still, the initial data is a boost to the Danish drugmaker’s hopes of winning back more share from its chief rival, Eli Lilly, this year in the booming obesity and diabetes drug market. Eli Lilly won the majority market share in early 2025 and is trailing closely behind Novo Nordisk in the pill space, as it prepares for the upcoming launch of its own oral drug for obesity.

    In a Friday note, Leerink Partners analyst David Risinger said around 3,100 prescriptions for the Wegovy pill were filled in the first week of the launch, citing IQVIA data for the week ending Jan. 9. In the first week of the commercial launch of Eli Lilly’s popular obesity injection, Zepbound, around 1,300 prescriptions were filled, and roughly 8,000 were filled in the second week, he noted. That injection won U.S. approval in late 2023. 

    The TD Cowen analysts cited somewhat different data published by Symphony through Bloomberg.

    The analysts said around 4,290 prescriptions were filled for Novo Nordisk’s pill during its first full week of launch, with the majority being for the starting dose of the drug. They added that the data from their source or IQVIA likely don’t include prescriptions through Novo Nordisk’s direct-to-consumer pharmacy or its telehealth partners. 

    The analysts said that compares with the roughly 1,900 prescriptions filled for Zepbound during its first full week on the market.

    Assuming the Symphony data is accurate, the pill “is already outstripping its injectable counterparts at the same stage of their launch,” TD Cowen analyst Michael Nedelcovych wrote in the note. A more direct comparison between the pill and the injections can be made based on available data early next week, though the figures may not prove more useful for another two to three quarters, he added. 

    Nedelcovych said he wants to see the full picture on the direct-to-consumer channel, which holds “significant promise” for the pill’s launch. 

    Demand could also shift once Eli Lilly’s pill, orforglipron, enters the market in the next few months, he added.

    While Novo Nordisk’s drug has a head start, it is a peptide medication with dietary requirements — no food or drink for 30 minutes after taking the pill with water — that may hinder uptake. Eli Lilly’s pill is a small-molecule drug and not a peptide, meaning it does not have those restrictions. 

    Novo Nordisk CEO: People have been waiting for a GLP-1 pill

    Read the original article here

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram

    You might also be interested in...

    Anthropic prices IPO at $83 a share, blowing past target range: report

    November 19, 2026

    California DMV boots Waymo robotaxis off state freeways after string of incidents

    November 18, 2026

    Chipotle launches Sneak It In hoodies with hidden pouch to keep your burrito warm

    November 17, 2026

    Big-ticket holiday items may be harder to find as shipping costs rise

    November 16, 2026

    Jensen Huang weighs Nvidia CEO comeback as ally plans war room: report

    November 16, 2026

    New Orleans port seeks tanker seizure after cruise ship crash sparks $1M lawsuit

    November 15, 2026
    Popular Posts

    Movie Review: Elsinore

    Interview with Aletheia von Gottlieb, Author of Love Off the Ice (Sweet Snowfall Kisses Book 1) – NewInBooks

    What Were Wearing: Friendsgiving

    In historic move, House Democrats nominate Hakeem Jeffries for speaker of the House

    Book Riots Deals of the Day for November 18, 2026

    Voyager 1 at one light-day: Historian revisits Golden Record's forgotten details

    Categories
    • Books (2,456)
    • Business (3,449)
    • Events (34)
    • Film (1,062)
    • LifeStyle (2,922)
    • Music (2,796)
    • Politics (2,355)
    • Science (1,951)
    • Technology (1,817)
    • Television (3,628)
    • US News (3,294)
    Archives
    Useful Links
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Popular Posts
    • 8 Chic Outfits Fashion People Are Wearing to Restaurants8 Chic Outfits Fashion People Are Wearing to Restaurants
    • Sockwell Socks Review: Sustainable, American-Made Merino Wool ComfortSockwell Socks Review: Sustainable, American-Made Merino Wool Comfort
    • The Blacklist Season 10 Episode 19 Spoilers: Reddington Takes a Shot at the US Government
    • How to Host a Dinner PartyHow to Host a Dinner Party
    • The #1 Jewelry Trend to Know For Summer 2026The #1 Jewelry Trend to Know For Summer 2026
    Archives
    Categories
    • Books
    • Business
    • Events
    • Film
    • LifeStyle
    • Music
    • Politics
    • Science
    • Technology
    • Television
    • US News
    Facebook X (Twitter) Instagram YouTube TikTok
    © 2026 Chicago News Journal. All rights reserved. All articles, images, product names, logos, and brands are property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Terms of Use and Privacy Policy.

    Type above and press Enter to search. Press Esc to cancel.